Refractoriness of aggressive behaviour to pharmacological treatment: cortical thickness analysis in autism spectrum disorder

Flavia Venetucci Gouveia, Jürgen Germann, Gabriel A. Devenyi, Rosa M. C. B. Morais, Ana Paula M. Santos, Erich T. Fonoff, Clement Hamani, Helena Brentani, M. Mallar Chakravarty and Raquel C. R. Martinez

Autism spectrum disorder (ASD) encompasses a range of neurodevelopmental disorders characterised by impairments in social interaction, communication deficits, restricted interests and repetitive behaviours. Although some individuals with ASD are able to live independently, others present with severe impairments causing great disability and impoverished quality of life (QoL). Furthermore, aggressive behaviours towards self (self-injurious behaviour) and others, is highly prevalent in individuals with ASD. Gold-standard aggressive behaviour therapies involve prescription drugs and psychotherapy and are effective in most patients. However, there is a subset (approximately 30%) that do not respond to treatment and are considered to have refractory aggressive behaviour (rAB). These patients are more challenging to treat and pose a high caregiver burden requiring specialised care. Given these challenges, efforts to find novel treatments, improve care and reduce suffering are paramount. Thus, studying the neurobiological underpinnings of rAB and identifying associated brain characteristics is essential to develop novel therapeutics.

It is believed that the neurocircuitry of aggressive behaviour involves cortical and limbic regions (for example prefrontal cortex; amygdala) and excessive aggressive behaviour occurs as a result of neurotransmission imbalances within these regions, but the neurobiological mechanisms underlying rAB are still unknown. Patients with aggressive behaviour are difficult to study as they are not collaborative in clinical settings and require deep sedation for image acquisition. However, as the chronic use of antipsychotics and benzodiazepines increases the risk of respiratory depression and death during sedation these types of interventions need to be restricted to the minimum. In this study, we had a unique opportunity to investigate the brain signature of individuals with rAB for a small group of patients with ASD with severe aggressive behaviour who had magnetic resonance imaging (MRI) for clinical purposes to investigate possible injuries to deep regions of the brain. Over the last 20 years, this technique has been applied to assess brain morphological patterns. Elucidating the neurobiology of refractory aggressive behaviour is crucial to provide insights and potential avenues for new interventions.

Keywords
Autistic spectrum disorders; intellectual disability; neuroimaging; cortical thickness; aggressive behaviour.

Copyright and usage
© The Author(s), 2020. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

Method
Participants
We report on ten patients with ASD associated with intellectual disabilities and severe aggressive behaviour, hallmarked by life-threatening self-injurious behaviour, aggression towards surroundings and others (rAB group: n = 3, 19–29 years; nrAB group: n = 7, 11–24 years; all males with normal karyotype 46, XY). rAB was defined as persistent aggressive behaviour despite previous trials of mono- and polypharmacy strategies of Food and Drug Administration-approved antipsychotics targeting aggressive behaviour (see Supplementary Table 1 available at https://doi.org/10.1192/bjo.2020.71: demographics and laboratory blood tests; Supplementary Table 2: medication history).

Questionnaires quantified severity of ASD (Childhood Autism Rating Scale, CARS), aggressive behaviour (Overt Aggression Scale), general motor agitation (Agitated Behaviour Scale) and QoL (Short Form Health Survey). Imaging acquisition was contemporaneous to surveys and laboratory blood tests. As patients presented with severe intellectual disability, neuropsychological evaluations were deferred and all questionnaires were reported by caregivers. The authors assert that all procedures contributing to this work comply with the ethical standards of the Research Ethical Board of the University of Sao Paulo, Medical School, Brazil and with the Helsinki Declaration of 1975, as revised in 2008. All procedures were approved by the REB (CAPesq#742.331; CAAE#31828014.6.3001.5461) and written informed consent was obtained from the patient’s caregivers.

MRI acquisition and image processing
Scans were obtained under deep sedation on a 1.5 Tesla MRI system (Magnetom Espree, Siemens, Germany). T1-weighted structural images were acquired (slice thickness:1.0 mm, no gap, echo time (TE)/repetition time (TR): 5/300 ms, flip angle:45°, field of view
(FOV): 240 mm, 1 × 0.9 × 0.9 mm or 1 × 0.5 × 0.5 mm voxel). Images were non-uniformity corrected using minc-hpipe-library (iterativeN4, https://github.com/CobraLab/minc-hpipe-library) and further processed using CIVET (v2.1.0; http://www.bic.mni.mcgill.ca/ServicesSoftware/CIVET) as described previously. Briefly, $T_1$-weighted images were non-linearly registered to MNI152 space and tissue classification (grey matter, white matter, cerebrospinal fluid) was performed using tissue classification priors. The white matter and pial surfaces were extracted and registered to the MNI152 surface template. Cortical thickness was then computed at each vertex based on the distance between grey and white matter surfaces using the laplacian method and blurred with a 40 mm geodesic surface kernel.

**Statistical analysis**

The RMINC (v1.5.2.0, https://github.com/Mouse-Imaging-Centre/RMINC) package in R (versus3.4.4, https://www.r-project.org/) was used to perform cortical thickness analyses. To investigate brain-wide differences in cortical thickness patterns related to group (rAB versus nrAB), a linear model of thickness by group using individual mean cortical thickness as covariate to correct for global differences was computed at each vertex. All analyses were corrected for multiple comparisons using false discovery rate (FDR) at $P_{FDR_{cor}} < 0.05$ threshold. Pearson correlations and t-tests were performed for demographics analysis.

**Results**

All participants in both groups had CARS score above 47 points indicating severe autism (rAB: mean 52 (s.d. = 3.6); nrAB: mean 51.6 (s.d. = 2.99). There were no differences between groups in age (rAB: mean 25 years (s.d. = 5.29); nrAB: mean 18.3 years (s.d. = 4.61); $t = -1.9092, d.f. = 3.3922, P = 0.1415$) and aggressive behaviour using the overt aggression scale (rAB: mean 11.7...
The results suggest that individuals with rAB are more severely impaired than those with nrAB as they present with greater levels of agitation and lower QoL. The correlation between agitation and aggressive behaviour is an important factor when treating patients with aggressive behaviour as targeting this particular symptom could lead to reductions in aggressive behaviour and improvement in QoL. The cortical thickness analysis revealed significant differences in brain morphology between groups: (a) mean whole-brain cortical thickness is reduced in rAB and (b) brain-wide pattern shows local deviations in key regions related to emotional control and aggressive behaviour. These results suggest that refractoriness to treatment could be associated with a characteristic cortical thickness phenotype. It is important to highlight, however, that this analysis was performed in a small group of male patients with clinical indications for MRI. These patients presented with severe self-injury behaviour towards the face and head that could lead to fractures and brain injury. Only patients with normal radiological examination were included. Also, some of the medications used for the control of aggressive behaviour are only prescribed in adulthood, the refractory group was composed of adults exclusively. All those in the refractory group had received at different times high-dose monotherapy and polypharmacy therapies. The possible side-effects of these therapies are poorly understood and worsening of the symptoms has been attributed to these treatments in some cases. It is known that individuals with ASD present with greater cortical thickness than healthy controls. However, the brain pattern differences found when the rAB and nrAB groups were compared were dissimilar to those found when comparing participants with ASD with healthy controls. The fine tuning within fronto-limbic-striatal circuits, in particular between the prefrontal cortex, amygdala and hypothalamus, is fundamental for behavioural control and aberrations affecting the structure or function of these regions can result in excessive aggressive behaviour.

Non-invasive neuromodulation therapies (for example transcranial magnetic stimulation; transcranial direct current stimulation) are currently being investigated for the treatment of neuropsychological symptoms, such as aggressive behaviour and agitation. These techniques can alter cortical excitability, resulting in widespread connectivity modifications and restoration of normal connectivity patterns. More recently, low-intensity focused ultrasound has emerged as a neuromodulatory alternative to target deep cortical areas and subcortical structures. With this rationale in mind, it is possible to propose the use of neuromodulatory therapies targeting one or more of these key brain regions (for example dlPFC, mPFC, ACC) to modulate local neural activity in an attempt to restore medication responsiveness in rAB. Further work with this group with rare and severe conditions is necessary to better understand the causes of cortical thickness changes, improve treatment options and reduce suffering.

Discussion

The results suggest that individuals with rAB are more severely impaired than those with nrAB as they present with greater levels of agitation and lower QoL. The correlation between agitation and aggressive behaviour is an important factor when treating patients with aggressive behaviour as targeting this particular symptom could lead to reductions in aggressive behaviour and improvement in QoL. The cortical thickness analysis revealed significant differences in brain morphology between groups: (a) mean whole-brain cortical thickness is reduced in rAB and (b) brain-wide pattern shows local deviations in key regions related to emotional control and aggressive behaviour. These results suggest that refractoriness to treatment could be associated with a characteristic cortical thickness phenotype. It is important to highlight, however, that this analysis was performed in a small group of male patients with clinical indications for MRI. These patients presented with severe self-injury behaviour towards the face and head that could lead to fractures and brain injury. Only patients with normal radiological examination were included. Also, some of the medications used for the control of aggressive behaviour are only prescribed in adulthood, the refractory group was composed of adults exclusively. All those in the refractory group had received at different times high-dose mootherapy and polypharmacy therapies. The possible side-effects of these therapies are poorly understood and worsening of the symptoms has been attributed to these treatments in some cases.

It is known that individuals with ASD present with greater cortical thickness than healthy controls. However, the brain pattern differences found when the rAB and nrAB groups were compared were dissimilar to those found when comparing participants with ASD with healthy controls. The fine tuning within fronto-limbic-striatal circuits, in particular between the prefrontal cortex, amygdala and hypothalamus, is fundamental for behavioural control and aberrations affecting the structure or function of these regions can result in excessive aggressive behaviour. Non-invasive neuromodulation therapies (for example transcranial magnetic stimulation; transcranial direct current stimulation) are currently being investigated for the treatment of neuropsychological symptoms, such as aggressive behaviour and agitation. These techniques can alter cortical excitability, resulting in widespread connectivity modifications and restoration of normal connectivity patterns. More recently, low-intensity focused ultrasound has emerged as a neuromodulatory alternative to target deep cortical areas and subcortical structures. With this rationale in mind, it is possible to propose the use of neuromodulatory therapies targeting one or more of these key brain regions (for example dlPFC, mPFC, ACC) to modulate local neural activity in an attempt to restore medication responsiveness in rAB. Further work with this group with rare and severe conditions is necessary to better understand the causes of cortical thickness changes, improve treatment options and reduce suffering.

Flavia Venetucci Gouveia, Sunnybrook Research Institute, Canada, and Hospital Sirio-Libanes, Brazil; Jürgen Germann, University Health Network; and CIC, Douglas Mental Health University Institute, McGill University, Canada; Gabriel A. Devenyi, CIC, Douglas Mental Health University Institute, McGill University, Canada; Department of Psychiatry, McGill University, Canada; Rosa M. C. B. Morales, Hospital Sirio-Libanes; and Department of Psychiatry, University of Sao Paulo, Medical School, Brazil; Ana Paula M. Santos, Department of Psychiatry, University of Sao Paulo, Medical School, Brazil; Erich T. Fonoff, Department of Neurology, Division of Functional Neurosurgery of the Institute of Psychiatry, University of Sao Paulo, Medical School, Brazil; Clement Hamani, Sunnybrook Research Institute, Harquhal Centre for Neuromodulation, Sunnybrook Health Sciences Centre; and Division of Neurosurgery, Sunnybrook Health Sciences Centre, University of Toronto, Canada; Helena Brentani, Department of Psychiatry, University of Sao Paulo, Medical School, Brazil; M. Malker Chakravarty, CIC, Douglas Mental Health University Institute, McGill University, Canada; Department of Psychiatry, McGill University, Canada; and Department of Biomedical and Biomedical Engineering, McGill University, Canada; Raquel C. R. Martinez, Hospital Sirio-Libanes; and Department of Psychiatry, University of Sao Paulo, Medical School, Brazil

Correspondence: Flavia Venetucci Gouveia. Email: flaviavenetucci@gmail.com

First received 8 Apr 2020; final revision 23 Jun 2020, accepted 12 Jul 2020

Supplementary material

Supplementary material is available online at http://doi.org/10.1192/bjp.2020.71

Data availability

All data generated and analysed during this study are available from the corresponding author upon reasonable request.

Acknowledgements

The authors wish to thank the research assistants and staff of Hospital Sirio-Libanes, Brazil and of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, Brazil.

Author contributions

F.V.G.: design of the work, acquisition, analysis and interpretation of data; drafting the manuscript and final approval of the version to be published. J.G.: analysis and interpretation of data; critical revision of the manuscript and final approval of the version to be published. M.C.: interpretation of data; critical revision of the manuscript and final approval of the version to be published. R.C.R.M.: design of the work, acquisition of data; critical revision of the manuscript and final approval of the version to be published. H.B.: acquisition of data; critical revision of the manuscript and final approval of the version to be published. A.P.M.S.: acquisition of data; critical revision of the manuscript and final approval of the version to be published. J.G.: analysis and interpretation of data; drafting the manuscript and final approval of the version to be published. F.V.G.: design of the work, acquisition, analysis and interpretation of data; drafting the manuscript and final approval of the version to be published.

Funding

This work was supported by grants FAPESP #11/08575-7 (R.C.R.M), #13/20602-5 (F.V.G.) and #13/10466-8 (F.V.G.) from the Brazil government. This research was enabled in part by support provided by SchNet (www.schnetpc.ca) and Compute Canada (www.computecanada.ca).

Declaration of interest

None.

ICMJE forms are in the supplementary material, available online at https://doi.org/10.1192/bjp.2020.71

References

1 Brentani H, de Paula CS, Bordini D, Rolim D, Sato F, Portoleses J, et al. Autism spectrum disorders: an overview on diagnosis and treatment. Rev Bras Psiquiatr 2013; 35: 562–72.
2 Gouveia FV, Germann J, de Morais RMCB, Fonoff ET, Hamani C, Alho EJ, et al. Clinical, imaging genetics and deformation based morphometry study of longitudinal changes after surgery for intractable aggressive behaviour. Neurosurgery 2020; Accepted for publication. Available from: https://www.biorxiv.org/content/10.1101/548826v2.

3 Adler BA, Wink LJ, Early M, Shaffer R, Minshawi N, McDougle CJ, et al. Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study. Autism 2015; 19: 102–6.

4 Gouveia FV, Hamani C, Fonoff ET, Brentani H, Alho EJL, de Morais RMCB, et al. Amygdala and hypothalamus: historical overview with focus on aggression. Neurosurgery 2019; 85: 11–30.

5 Blair RJR. The Neurobiology of Impulsive Aggression. J Child Adolesc Psychopharmacol 2016; 26: 4–9.

6 Bedford SA, Park MTM, Devenyi GA, Tullo S, Germann J, Patel R, et al. Large-scale analyses of the relationship between sex, age and intelligence quotient heterogeneity and cortical morphometry in autism spectrum disorder. Mol Psychiatry 2020; 25: 614–28.

7 Morrissette DA, Stahl SM. Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr 2014; 19: 439–48.

8 Myers SM. The status of pharmacotherapy for autism spectrum disorders. Expert Opin Pharmacother 2007; 8: 1579–603.

9 Vacas SM, Stella F, Loureiro IJ, Simões do Couto F, Oliveira-Maia AJ, Forlenza OV. Noninvasive brain stimulation for behavioural and psychological symptoms of dementia: A systematic review and meta-analysis. Int J Geriatr Psychiatry 2019; 34: 1336–45.

10 Klomjai W, Katz R, Lackmy-Vallee A. Basic principles of transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS). Ann Phys Rehabil Med 2015; 58: 208–13.

11 Reato D, Salvador R, Bikson M, Opitz A, Dmochowski J, Miranda PC. Principles of transcranial direct current stimulation (tDCS): introduction to the biophysics of tDCS. In Practical Guide to Transcranial Direct Current Stimulation (eds H Knotkova, MA Nitsche, M Bikson, AJ Woods): 45–80. Springer, 2019.

12 Baek H, Pahk KJ, Kim H. A review of low-intensity focused ultrasound for neuromodulation. Biomed Eng Lett 2017; 7: 135–42.